Enthera Pharmaceuticals
Italian biotechnology company developing first-in-class biologics targeting the IGFBP3/TMEM219 pathway to transform the treatment of autoimmune conditions including Type 1 diabetes.
Notes
Enthera Pharmaceuticals is an Italian biotechnology company headquartered in Milan, focused on developing first-in-class biologics for autoimmune diseases. The company is targeting the IGFBP3/TMEM219 pathway, a novel mechanism involved in immune regulation and beta cell protection.
Enthera's lead program is focused on Type 1 diabetes, where the company's approach aims to preserve and restore beta cell function while modulating the autoimmune response. This represents a potential disease-modifying approach rather than symptomatic treatment.
The company is part of the Sofinnova Partners portfolio and has raised funding to advance its clinical development programs.
Team
- Paolo Fiorina, M.D., Ph.D. - Co-founder & Chief Scientific Officer
- Leadership team available on company website
Additional Research Findings
- Founded in 2016
- Portfolio company of Sofinnova Partners
- Headquarters: Milan, Italy
- Focus on autoimmune disease therapeutics
- First-in-class biologics platform
- Novel IGFBP3/TMEM219 pathway target
- Lead indication: Type 1 diabetes
- Disease-modifying approach to autoimmune conditions
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |